AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK).

The Japanese drug maker will use Iambic's AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda's oncology, gastrointestinal, and inflammation therapeutic areas.

Through the agreement, Takeda will also gain access to NeuralPLexer, Iambic's model for predicting protein-ligand complexes.

Based in San Diego and founded in 2020, Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform.

Iambic's Collaboration Could Exceed $1.7 Billion

"Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates," said Tom Miller, Co-Founder and CEO of ...